[Experience with imatinib to treat pulmonary arterial hypertension]

Arch Bronconeumol. 2008 Dec;44(12):689-91. doi: 10.1016/s1579-2129(09)60008-2.
[Article in Spanish]

Abstract

Despite advances in the treatment of patients with pulmonary arterial hypertension (PAH), survival has not improved greatly (is still very affected). Imatinib, an antagonist of platelet-derived growth factor with antiproliferative activity, has been effective in experimental models and clinically in several published reports. We report the results of imatinib therapy in 4 patients with PAH (functional class IV) who were refractory to treatment with drug combinations for this condition. The final outcome was favorable in only 1 of the 4 cases. In this case, the patient was in functional class III and his hemodynamic parameters had improved significantly within 5 months after starting therapy. However, the patient died as a result of severe toxic hepatitis in which imatinib may have played a role. The present report adds to the few already in the literature (4 cases) and suggests that care should continue to be shown when using imatinib to treat PAH.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamides
  • Chemical and Drug Induced Liver Injury / etiology
  • Fatal Outcome
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Imatinib Mesylate
  • Middle Aged
  • Piperazines / adverse effects
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use*
  • Platelet-Derived Growth Factor / antagonists & inhibitors*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Platelet-Derived Growth Factor
  • Pyrimidines
  • Imatinib Mesylate